Andrew Gibbons1, Brian Dean. 1. The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, Australia. agibbons@unimelb.edu.au.
Abstract
BACKGROUND: Cognitive deficits are amongst the most socially debilitating and least effectively treated symptoms of schizophrenia. The cholinergic system is a promising target for the design of novel drugs that can more effectively treat these symptoms. METHODS: We review the literature supporting the dysfunction of the cholinergic system in schizophrenia, discuss the preclinical and clinical data showing that modulating the cholinergic system could improve the symptoms of schizophrenia and review the main pharmacological strategies being investigated to treat cholinergic dysfunction in schizophrenia. RESULTS: Post-mortem and neuroimaging studies suggest there are widespread reductions in cholinergic receptor signalling in the cortex as well as subcortical regions, such as the hippocampus and striatum, in individuals with schizophrenia. Potential cholinergic drug targets are being pursued to increase receptor function. These include inhibiting the activity of the enzyme acetylcholinesterase to increase synaptic acetylcholine levels, and increasing the nicotinic receptor and muscarinic receptor activity with agonists or positive allosteric modulators. CONCLUSION: Amongst the most promising drug targets for treating schizophrenia are the α7 nicotinic receptor and the CHRM1 and CHRM4 muscarinic receptors. The recent development of allosteric modulators that selectively target these receptors offers the potential to more effectively treat the symptoms of schizophrenia.
BACKGROUND:Cognitive deficits are amongst the most socially debilitating and least effectively treated symptoms of schizophrenia. The cholinergic system is a promising target for the design of novel drugs that can more effectively treat these symptoms. METHODS: We review the literature supporting the dysfunction of the cholinergic system in schizophrenia, discuss the preclinical and clinical data showing that modulating the cholinergic system could improve the symptoms of schizophrenia and review the main pharmacological strategies being investigated to treat cholinergic dysfunction in schizophrenia. RESULTS: Post-mortem and neuroimaging studies suggest there are widespread reductions in cholinergic receptor signalling in the cortex as well as subcortical regions, such as the hippocampus and striatum, in individuals with schizophrenia. Potential cholinergic drug targets are being pursued to increase receptor function. These include inhibiting the activity of the enzyme acetylcholinesterase to increase synaptic acetylcholine levels, and increasing the nicotinic receptor and muscarinic receptor activity with agonists or positive allosteric modulators. CONCLUSION: Amongst the most promising drug targets for treating schizophrenia are the α7 nicotinic receptor and the CHRM1 and CHRM4 muscarinic receptors. The recent development of allosteric modulators that selectively target these receptors offers the potential to more effectively treat the symptoms of schizophrenia.
Authors: Elizabeth Scarr; Shaun Hopper; Valentina Vos; Myoung Suk Seo; Ian Paul Everall; Timothy Douglas Aumann; Gursharan Chana; Brian Dean Journal: J Psychiatry Neurosci Date: 2018-08 Impact factor: 6.186
Authors: Yoshihiro Noda; Mera S Barr; Reza Zomorrodi; Robin F H Cash; Tarek K Rajji; Faranak Farzan; Robert Chen; Tony P George; Zafiris J Daskalakis; Daniel M Blumberger Journal: Schizophr Bull Date: 2018-01-13 Impact factor: 9.306
Authors: Carolin Hoffmann; Jo Stevens; Shenghua Zong; Daan van Kruining; Abhishek Saxena; Cem İsmail Küçükali; Erdem Tüzün; Nazlı Yalçınkaya; Marc De Hert; Emiliano González-Vioque; Celso Arango; Jon Lindstrom; Marc H De Baets; Bart P F Rutten; Jim van Os; Peter Molenaar; Mario Losen; Pilar Martinez-Martinez Journal: PLoS One Date: 2018-12-06 Impact factor: 3.240